IE42622B1 - Protective antigen from pertussis, process for its preparation and products containing this antigen - Google Patents
Protective antigen from pertussis, process for its preparation and products containing this antigenInfo
- Publication number
- IE42622B1 IE42622B1 IE2807/75A IE280775A IE42622B1 IE 42622 B1 IE42622 B1 IE 42622B1 IE 2807/75 A IE2807/75 A IE 2807/75A IE 280775 A IE280775 A IE 280775A IE 42622 B1 IE42622 B1 IE 42622B1
- Authority
- IE
- Ireland
- Prior art keywords
- denaturing agent
- antigen
- protective antigen
- concentration
- pathogens
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 31
- 101710194807 Protective antigen Proteins 0.000 title claims abstract description 27
- 239000000427 antigen Substances 0.000 title claims abstract description 17
- 102000036639 antigens Human genes 0.000 title claims abstract description 17
- 108091007433 antigens Proteins 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 201000005702 Pertussis Diseases 0.000 title claims description 22
- 244000052769 pathogen Species 0.000 claims abstract description 33
- 241000588832 Bordetella pertussis Species 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 229960005486 vaccine Drugs 0.000 claims description 10
- 239000003463 adsorbent Substances 0.000 claims description 9
- 230000007935 neutral effect Effects 0.000 claims description 8
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 7
- 239000002609 medium Substances 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000007791 liquid phase Substances 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 238000005227 gel permeation chromatography Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- 239000012736 aqueous medium Substances 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 2
- 229920000620 organic polymer Polymers 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 239000011541 reaction mixture Substances 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical group [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 238000000605 extraction Methods 0.000 abstract description 11
- 229940066827 pertussis vaccine Drugs 0.000 abstract description 9
- 230000001681 protective effect Effects 0.000 description 10
- 239000000284 extract Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 238000003916 acid precipitation Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 239000002156 adsorbate Substances 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 150000008045 alkali metal halides Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- -1 for example Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2461439A DE2461439C3 (de) | 1974-12-24 | 1974-12-24 | Verfahren zur Herstellung eines schützenden Antigens von Bordetella Pertussis sowie jenes enthaltendes Mittel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE42622L IE42622L (en) | 1976-06-24 |
| IE42622B1 true IE42622B1 (en) | 1980-09-10 |
Family
ID=5934586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE2807/75A IE42622B1 (en) | 1974-12-24 | 1975-12-23 | Protective antigen from pertussis, process for its preparation and products containing this antigen |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4029766A (enExample) |
| JP (1) | JPS6222970B2 (enExample) |
| AT (1) | AT355203B (enExample) |
| BE (1) | BE837082A (enExample) |
| CA (1) | CA1059027A (enExample) |
| CH (1) | CH628246A5 (enExample) |
| DE (1) | DE2461439C3 (enExample) |
| DK (1) | DK143317C (enExample) |
| ES (1) | ES443624A1 (enExample) |
| FR (1) | FR2295758A1 (enExample) |
| GB (1) | GB1537849A (enExample) |
| IE (1) | IE42622B1 (enExample) |
| IL (1) | IL48730A (enExample) |
| LU (1) | LU74088A1 (enExample) |
| MX (1) | MX3785E (enExample) |
| NL (1) | NL7514858A (enExample) |
| SE (1) | SE431057B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2393065A1 (fr) * | 1977-05-31 | 1978-12-29 | Merieux Inst | Procede de separation de lipides d'endotoxines bacteriennes et notamment d'endotoxine de bordetella pertussis |
| DE2862449D1 (en) * | 1977-08-22 | 1984-11-22 | Nat Res Dev | Macromolecular covalent conjugates, methods for preparing and pharmaceutical compositions containing them |
| US4196192A (en) * | 1977-10-28 | 1980-04-01 | American Cyanamid Company | Combined Haemophilus influenzae type b and pertussis vaccine |
| NZ188211A (en) * | 1977-10-28 | 1984-09-28 | American Cyanamid Co | Isolation of polyribosyl ribitol phosphate(prp)from haemophilus influenzae type b;vaccine comprising prp and bordetellapertussis antigens |
| EP0004137B1 (en) * | 1978-02-17 | 1981-11-11 | National Research Development Corporation | Immunogenic cell envelope preparations |
| US4247452A (en) * | 1978-03-01 | 1981-01-27 | The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland | Purification of pertussis haemagglutinins |
| US4338299A (en) * | 1980-11-17 | 1982-07-06 | Dso "Pharmachim" | Vaccine against pertussis |
| GB2144129B (en) * | 1981-08-24 | 1985-10-09 | Vilas V Likhite | Antigens as immunostimulant adjuvants |
| HU188847B (en) * | 1983-02-22 | 1986-05-28 | Human Oltoanyagtermeloe Es Kutato Intezet,Hu | Process for producing liophylized combined vaccines |
| US4705686A (en) * | 1986-05-09 | 1987-11-10 | American Cyanamid | Process for the preparation of acellular Bordetalla pertussis vaccine |
| US4845036A (en) * | 1987-02-03 | 1989-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Process for isolation of the B oligomer of pertussis toxin |
| CA1337859C (en) * | 1987-04-24 | 1996-01-02 | Masashi Chazono | Method for culturing bordetella pertussis, a pertussis toxoid and a pertussis vaccine |
| US5139776A (en) * | 1987-04-24 | 1992-08-18 | The Research Foundation For Microbial Diseases Of Osaka University | Method for culturing Bordetella pertussis, a pertussis toxoid and a pertussis vaccine |
| GB9924351D0 (en) * | 1999-10-14 | 1999-12-15 | Brennan Frank | Immunomodulation methods and compositions |
| US20090093019A1 (en) * | 2007-04-27 | 2009-04-09 | Phelps Jamie P | Production and in vivo assembly of soluble recombinant icosahedral virus-like particles |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3141824A (en) * | 1961-05-19 | 1964-07-21 | Lilly Co Eli | Pertussis antigen |
| US3395219A (en) * | 1964-12-11 | 1968-07-30 | Merck & Co Inc | Process for production of pertussis antigen |
| US3405218A (en) * | 1965-09-22 | 1968-10-08 | Parke Davis & Co | Extracting bordetella pertussis antigens with lithium bromide |
| US3465078A (en) * | 1965-10-21 | 1969-09-02 | Sydney Z Spiesel | Method of recovering antigens from bordetella pertussis cells |
-
1974
- 1974-12-24 DE DE2461439A patent/DE2461439C3/de not_active Expired
-
1975
- 1975-12-18 ES ES443624A patent/ES443624A1/es not_active Expired
- 1975-12-19 NL NL7514858A patent/NL7514858A/xx not_active Application Discontinuation
- 1975-12-22 DK DK586575A patent/DK143317C/da not_active IP Right Cessation
- 1975-12-22 US US05/643,123 patent/US4029766A/en not_active Expired - Lifetime
- 1975-12-22 CH CH1660875A patent/CH628246A5/de not_active IP Right Cessation
- 1975-12-22 LU LU74088A patent/LU74088A1/xx unknown
- 1975-12-23 IE IE2807/75A patent/IE42622B1/en unknown
- 1975-12-23 AT AT980275A patent/AT355203B/de not_active IP Right Cessation
- 1975-12-23 SE SE7514601A patent/SE431057B/xx not_active IP Right Cessation
- 1975-12-23 CA CA242,453A patent/CA1059027A/en not_active Expired
- 1975-12-24 FR FR7539711A patent/FR2295758A1/fr active Granted
- 1975-12-24 IL IL7548730A patent/IL48730A/xx unknown
- 1975-12-24 BE BE163118A patent/BE837082A/xx not_active IP Right Cessation
- 1975-12-24 JP JP50153512A patent/JPS6222970B2/ja not_active Expired
- 1975-12-24 GB GB52894/75A patent/GB1537849A/en not_active Expired
-
1976
- 1976-01-05 MX MX766631U patent/MX3785E/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATA980275A (de) | 1979-07-15 |
| IE42622L (en) | 1976-06-24 |
| US4029766A (en) | 1977-06-14 |
| AT355203B (de) | 1980-02-25 |
| DE2461439A1 (de) | 1976-07-01 |
| NL7514858A (nl) | 1976-06-28 |
| SE431057B (sv) | 1984-01-16 |
| DE2461439C3 (de) | 1980-03-20 |
| GB1537849A (en) | 1979-01-04 |
| JPS6222970B2 (enExample) | 1987-05-20 |
| CH628246A5 (de) | 1982-02-26 |
| BE837082A (fr) | 1976-06-24 |
| LU74088A1 (enExample) | 1976-11-11 |
| DE2461439B2 (de) | 1979-07-12 |
| DK143317C (da) | 1981-12-28 |
| ES443624A1 (es) | 1977-04-16 |
| MX3785E (es) | 1981-07-16 |
| JPS5188623A (enExample) | 1976-08-03 |
| FR2295758A1 (fr) | 1976-07-23 |
| CA1059027A (en) | 1979-07-24 |
| DK143317B (da) | 1981-08-10 |
| DK586575A (da) | 1976-06-25 |
| SE7514601L (sv) | 1976-06-25 |
| FR2295758B1 (enExample) | 1979-06-29 |
| AU8780875A (en) | 1977-06-30 |
| IL48730A0 (en) | 1976-02-29 |
| IL48730A (en) | 1978-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IE42622B1 (en) | Protective antigen from pertussis, process for its preparation and products containing this antigen | |
| Bremell et al. | Experimental Staphylococcus aureus arthritis in mice | |
| DE68928432T2 (de) | Legionellosis-impfstoffe und verfahren zur herstellung | |
| CN107080842A (zh) | 抗体制剂 | |
| HU185404B (en) | Process for preparing pertussis toxoide | |
| JPH0840932A (ja) | スタフイロコッカス属菌感染症の予防ワクチン及び治療用抗体並びにそれの製造法 | |
| US3608071A (en) | Manufacturing adsorbed vaccines | |
| TW201514197A (zh) | 類毒素、組合物及相關方法 | |
| KR0162074B1 (ko) | 항원용액중의 보조제로서 수산화아연 또는 수산화철의 용도, 및 이러한 보조제를 함유하는 항원용액 | |
| CA1290690C (en) | Method of reducing the swelling or pain associated with antibiotics compositions | |
| JPH07501333A (ja) | グラム陰性菌ワクチン | |
| CN105535964A (zh) | 一种具有免疫调节作用的双链聚核苷酸—ε-聚赖氨酸—硫酸聚糖复合物及其制备使用方法 | |
| DE3782356T2 (de) | Reinigungsverfahren der proteischen antigene von bordetella-bakterien zur gewinnung eines azellularen vakzins. | |
| DE69329922T3 (de) | Herstellung eines tetanusimpfstoffes | |
| EP0065787B1 (en) | Immunopotentiator | |
| US3859435A (en) | Basic derivatives of lysozyme | |
| IE65211B1 (en) | The use of zinc calcium hydroxide lecithin and PAO as an adjuvant for antigen solutions and antigen solutions treated with an adjuvant of this type | |
| Schleimer et al. | Effects of prostaglandin synthesis inhibition on the immune response | |
| JP2634545B2 (ja) | Ｒｔｘトキシンファミリーに属する細菌毒素ワクチンの製造法 | |
| JPS6231720B2 (enExample) | ||
| US3968202A (en) | Tetanus antigen and process for its manufacture | |
| RU2404770C1 (ru) | Способ получения комплексного иммунотропного препарата для животных | |
| Tenbroeck et al. | Mustard inactivated rabies vaccine | |
| CA1302882C (en) | Vaccines and immunoglobulin g-containing preparations active against pseudomonas aeruginosa | |
| RU2148412C1 (ru) | Способ получения протективного коклюшного антигена |